search
Back to results

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Primary Purpose

Asthma

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AMG 282
AMG 282 Matching Placebo
Sponsored by
Amgen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Mild asthma, Atopic asthma, Healthy volunteers, First-in-human

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria (All subjects)

  • Is a current non-smoker, has not used any nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) within the last 6 months, and cumulative smoking history is ≤10 pack years.
  • Females must be of documented non-reproductive potential (ie, postmenopausal [see definition below]; OR history of hysterectomy; OR history of bilateral salpingectomy; OR history of bilateral oophorectomy).
  • Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg/m2 at screening. (Subjects with mild atopic asthma only)
  • Documented history of mild, stable atopic asthma within 2 years of screening.
  • Has used only inhaled short-acting β2-agonists (less than twice weekly) to treat asthma.
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) > 70% predicted at screening.

Exclusion Criteria

(All subjects)

  • History or evidence of a clinically significant disorder, condition or disease that, in the opinion of the Principal Investigator or Amgen medical monitor would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Subject has a history of residential exposure to tuberculosis without a documented history of prophylactic treatment of tuberculosis or subject has a positive purified protein derivative (PPD) or QuantiFERON test at screening. Subjects with a documented negative PPD or QuantiFERON test within 4 weeks prior to screening who have no known tuberculosis exposure and have not traveled to an area with tuberculosis do not need to have a test performed at screening.
  • Has donated or lost ≥ 500 mL of blood or plasma within 8 weeks of administration of the first dose of IP.

Other criteria may apply.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Experimental Arm

Placebo Arm

Arm Description

Outcomes

Primary Outcome Measures

Incidence of treatment emergent adverse events
Incidence of abnormal clinically significant vital signs
Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results
Incidence of abnormal clinically significant ECG results
Incidence of anti-AMG 282 antibodies

Secondary Outcome Measures

Determination of various PK parameters including tmax, AUClast and Cmax

Full Information

First Posted
August 21, 2013
Last Updated
December 13, 2016
Sponsor
Amgen
search

1. Study Identification

Unique Protocol Identification Number
NCT01928368
Brief Title
A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
Official Title
A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Amgen

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.
Detailed Description
A single SC or IV dose administration of AMG 282 to healthy subjects and subjects with mild atopic asthma will exhibit an acceptable safety and tolerability profile within the dose ranges studied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Mild asthma, Atopic asthma, Healthy volunteers, First-in-human

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Arm
Arm Type
Active Comparator
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
AMG 282
Intervention Description
Single dose either subcutaneously or intravenously on day 1.
Intervention Type
Drug
Intervention Name(s)
AMG 282 Matching Placebo
Intervention Description
Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
Primary Outcome Measure Information:
Title
Incidence of treatment emergent adverse events
Time Frame
Up to day 141
Title
Incidence of abnormal clinically significant vital signs
Time Frame
Up to day 141
Title
Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results
Time Frame
Up to day 141
Title
Incidence of abnormal clinically significant ECG results
Time Frame
Up to day 141
Title
Incidence of anti-AMG 282 antibodies
Time Frame
Up to 1 year
Secondary Outcome Measure Information:
Title
Determination of various PK parameters including tmax, AUClast and Cmax
Time Frame
Up to day 141
Other Pre-specified Outcome Measures:
Title
Measurement of various pharmacodynamic biomarkers in subjects with mild atopic asthma
Time Frame
Up to day 141

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria (All subjects) Is a current non-smoker, has not used any nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) within the last 6 months, and cumulative smoking history is ≤10 pack years. Females must be of documented non-reproductive potential (ie, postmenopausal [see definition below]; OR history of hysterectomy; OR history of bilateral salpingectomy; OR history of bilateral oophorectomy). Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg/m2 at screening. (Subjects with mild atopic asthma only) Documented history of mild, stable atopic asthma within 2 years of screening. Has used only inhaled short-acting β2-agonists (less than twice weekly) to treat asthma. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) > 70% predicted at screening. Exclusion Criteria (All subjects) History or evidence of a clinically significant disorder, condition or disease that, in the opinion of the Principal Investigator or Amgen medical monitor would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. Subject has a history of residential exposure to tuberculosis without a documented history of prophylactic treatment of tuberculosis or subject has a positive purified protein derivative (PPD) or QuantiFERON test at screening. Subjects with a documented negative PPD or QuantiFERON test within 4 weeks prior to screening who have no known tuberculosis exposure and have not traveled to an area with tuberculosis do not need to have a test performed at screening. Has donated or lost ≥ 500 mL of blood or plasma within 8 weeks of administration of the first dose of IP. Other criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MD
Organizational Affiliation
Amgen
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Cypress
State/Province
California
ZIP/Postal Code
90630
Country
United States
Facility Name
Research Site
City
Aventura
State/Province
Florida
ZIP/Postal Code
33180
Country
United States
Facility Name
Research Site
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
Facility Name
Research Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27612
Country
United States
Facility Name
Research Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98115
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.amgentrials.com
Description
AmgenTrials clinical trials website

Learn more about this trial

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

We'll reach out to this number within 24 hrs